

Table S.1 Meta-analysis of the associations between *CYP3A4* rs2242480, *CYP3A5* rs776746, *SCN1A* rs3812718 and rs2298771 polymorphisms and CBZ metabolism.

Polymorphism	Plasma concentration	Allelic model		Homozygote codominant model		Heterozygote codominant model		Dominant model		Recessive model		Overdominant model	
		SMD/MD (95% CI)	P	SMD/MD (95% CI)	P	SMD/MD (95% CI)	P	SMD/MD (95% CI)	P	SMD/MD (95% CI)	P	SMD/MD (95% CI)	P
rs2242480	CBZ	0.01 [-0.02, 0.04]	0.57	-0.07 [-0.43, 0.28]	0.69	-0.27 [-0.43, -0.11]	0.001*	-0.23 [-0.39, -0.08]	0.003*	0.04 [-0.31, 0.39]	0.82	-0.28 [-0.44, -0.12]	0.0006*
	CBZE	0.03 [-0.15, 0.21]	0.74	0.06 [-0.38, 0.49]	0.8	-0.15 [-0.52, 0.22]	0.42	-0.12 [-0.44, 0.20]	0.47	0.14 [-0.28, 0.56]	0.51	-0.16 [-0.52, 0.20]	0.38
	CBZD	/	/	-0.16 [-0.47, 0.15]	0.31	-0.14 [-0.30, 0.02]	0.09	-0.15 [-0.30, 0.00]	0.05	-0.11 [-0.41, 0.19]	0.48	-0.12 [-0.28, 0.04]	0.13
rs776746	CBZE:CBZ	-0.01 [-0.20, 0.18]	0.92	-0.04 [-0.08, -0.00]	0.04*	-0.01 [-0.04, 0.02]	0.43	-0.01 [-0.03, 0.01]	0.42	-0.04 [-0.08, -0.00]	0.03*	-0.01 [-0.03, 0.01]	0.42
	CBZ	0.02 [-0.02, 0.06]	0.27	0.68 [0.37, 1.00]	<0.0001*	0.16 [-0.19, 0.51]	0.36	0.38 [0.05, 0.72]	0.03*	0.57 [0.21, 0.92]	0.002*	-0.28 [-0.72, 0.17]	0.22
	CBZE	-0.14 [-0.32, 0.04]	0.13	-0.10 [-0.57, 0.38]	0.68	0.01 [-0.47, 0.49]	0.96	-0.04 [-0.51, 0.42]	0.86	-0.31 [-0.74, 0.12]	0.16	0.04 [-0.28, 0.37]	0.79
	CBZD	/	/	-0.08 [-0.48, 0.32]	0.69	-0.12 [-0.53, 0.29]	0.56	-0.09 [-0.48, 0.30]	0.65	0.03 [-0.12, 0.18]	0.7	-0.04 [-0.20, 0.12]	0.62
SA of rs776746	CBZE:CBZ	-0.01 [-0.03, 0.01]	0.3	0.03 [-0.01, 0.07]	0.12	0.03 [-0.01, 0.07]	0.13	0.03 [-0.01, 0.07]	0.1	0.00 [-0.02, 0.02]	1	0.00 [-0.02, 0.02]	1
	CBZ	/	/	/	/	/	/	/	/	0.69 [0.37, 1.02]	<0.0001*	-0.09 [-0.42, 0.23]	0.58
rs3812718	CBZE	/	/	/	/	/	/	/	/	-0.49 [-0.82, -0.17]	0.003*	/	/
	CBZ	-0.58[-0.73, -0.44]	<0.00001*	-0.03 [-1.33, 1.27]	0.96	-0.12 [-0.91, 0.67]	0.76	-0.12[-1.05, 0.82]	0.8	0.16[-0.71, 1.03]	0.72	-0.19[-0.30, -0.08]	0.001*
	CBZE	-0.06 [-0.22, 0.10]	0.47	-0.21 [-0.56, 0.14]	0.25	-0.06 [-0.32, 0.21]	0.68	-0.09 [-0.35, 0.16]	0.48	-0.24 [-0.53, 0.04]	0.09	0.07 [-0.16, 0.29]	0.56
	CBZD	/	/	0.05[-0.01, 0.11]	0.13	0.00 [-0.06, 0.06]	1	0.01 [-0.05, 0.07]	0.72	0.05 [-0.01, 0.11]	0.09	-0.01[-0.06, 0.04]	0.72
	CBZE:CBZ	0.00 [-0.02, 0.02]	1	0.32 [-0.03, 0.68]	0.07	0.32 [0.05, 0.59]	0.02*	0.29 [0.03, 0.55]	0.03*	-0.03[-0.31, 0.25]	0.83	0.22[0.00, 0.45]	0.05
SA of rs3812718	CBZD:CBZ	/	/	0.20 [0.11, 0.29]	<0.0001*	0.04 [-0.02, 0.10]	0.19	0.07 [0.01, 0.13]	0.02*	0.18 [0.09, 0.27]	<0.0001*	-0.01 [-0.07, 0.05]	0.75
	CBZD:CBZE	/	/	1.20 [-0.50, 2.90]	0.17	-0.22 [-1.09, 0.65]	0.62	0.02 [-0.84, 0.88]	0.96	1.33 [-0.28, 2.94]	0.11	-0.51 [-1.35, 0.33]	0.23
	CBZ	/	/	-0.48 [-1.30, 0.35]	0.26	-0.41 [-0.88, 0.07]	0.09	-0.44 [-1.03, 0.15]	0.15	-0.15 [-0.62, 0.33]	0.55	/	/
	CBZ	0.13 [-0.09, 0.35]	0.26	-0.15 [-0.53, 0.23]	0.45	0.03 [-0.17, 0.23]	0.78	0.29 [-0.43, 1.00]	0.44	-0.03 [-0.34, 0.28]	0.85	0.03 [-0.15, 0.21]	0.75
	CBZE	0.17 [-0.11, 0.45]	0.23	-0.09 [-0.49, 0.31]	0.66	-0.06 [-0.45, 0.33]	0.77	-0.06 [-0.43, 0.32]	0.77	0.06 [-0.26, 0.38]	0.7	-0.04 [-0.37, 0.29]	0.8
rs2298771	CBZD	/	/	0.01 [-0.06, 0.08]	0.76	0.02 [-0.05, 0.09]	0.57	0.02 [-0.04, 0.08]	0.54	-0.01 [-0.06, 0.04]	0.7	0.01 [-0.04, 0.06]	0.71
	CBZE:CBZ	0.03 [-0.00, 0.06]	0.06	0.15 [-0.33, 0.62]	0.55	0.27 [-0.02, 0.55]	0.06	0.27 [-0.01, 0.54]	0.06	-0.01 [-0.37, 0.35]	0.96	0.18 [-0.19, 0.56]	0.34
	CBZD:CBZ	/	/	0.07 [-0.01, 0.15]	0.07	0.04 [-0.03, 0.11]	0.27	0.05 [-0.02, 0.12]	0.13	0.04 [-0.02, 0.10]	0.22	0.00 [-0.06, 0.06]	1
	CBZD:CBZE	/	/	0.15 [-1.16, 1.46]	0.82	0.11 [-1.04, 1.26]	0.85	0.12 [-0.99, 1.23]	0.83	0.07 [-0.90, 1.04]	0.89	0.02 [-0.83, 0.87]	0.96
	CBZ	/	/	/	/	/	/	0.03 [-0.17, 0.22]	0.79	/	/	/	/
SA of rs2298771	CBZE	/	/	/	/	0.11 [-0.17, 0.39]	0.44	0.11 [-0.17, 0.38]	0.45	/	/	-0.18[-0.45, 0.09]	0.18

CBZ carbamazepine, CBZE carbamazepine-10,11-epoxide, CBZD carbamazepine-10,11-trans dihydrodiol, SA sensitivity analysis, SMD standard mean differences, MD mean differences, CI confidence interval, * *P*-value < 0.05, / not appreciable.

Table S.2 Meta-analysis of the associations between *CYP3A4* rs2242480, *CYP3A5* rs776746, *SCN1A* rs3812718 and rs2298771 polymorphisms and CBZ resistance.

Polymorphism	Allelic model		Homozygote codominant model		Heterozygote codominant model		Dominant model		Recessive model		Overdominant model	
	RR(95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P
rs2242480	0.90[0.49, 1.65]	0.74	/	/	1.15[0.67, 1.97]	0.62	1.04[0.62, 1.75]	0.88	/	/	1.23[0.71, 2.12]	0.46
rs776746	/	/	1.02[0.32, 3.27]	0.98	/	/	/	/	1.01[0.70, 1.47]	0.94	/	/
rs3812718	1.18[1.05, 1.33]	0.007*	1.24[1.08, 1.43]	0.003*	0.99[0.89, 1.11]	0.89	1.04[0.97, 1.12]	0.3	1.47[1.22, 1.77]	<0.0001*	0.82[0.66, 1.02]	0.07
rs2298771	1.32[0.70, 2.50]	0.39	1.60[0.50, 5.10]	0.43	1.23[0.73, 2.05]	0.43	1.15[0.87, 1.52]	0.32	1.46[0.52, 4.12]	0.47	1.07[0.82, 1.40]	0.6
SA of rs2298771	/	/	/	/	/	/	1.01[0.87, 1.16]	0.93	/	/	/	/

RR risk ratio, CI confidence interval, * *P*-value < 0.05, SA sensitivity analysis, / not appreciable.